Repligen | RGEN - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Agilent USD 465M 11M 2026-03
Align Technology USD 462.67M 2.67M 2026-06
Bio Techne USD 109.34M 4.35M 2026-03
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Bruker USD 238.9M 3.2M 2026-06
Charles River Laboratories USD 228.9M 69.47M 2026-06
Danaher USD 2.07B 212M 2026-06
Dentsply International USD 364M 13M 2026-06
General Electric Aerospace USD 1.13B 47M 2026-06
Henry Schein USD 831M 22M 2026-06
Illumina USD 273M 1000K 2026-06
IQVIA Holdings USD 574M 72M 2026-06
Mettler Toledo International USD 263.33M 5.01M 2026-06
Myriad Genetics USD 122.3M 6.7M 2025-12
OraSure Technologies USD 13.21M 3.29M 2025-12
Pacific Biosciences Of California USD 37.24M 25.68M 2025-12
Pfizer USD 3.41B 496M 2026-06
Repligen USD 76.62M 82K 2026-06
Revvity USD 278.58M 24.69M 2026-06
Standard Biotools USD 18.61M 2.94M 2026-03
Thermo Fisher Scientific USD 1.91B 111M 2026-06
Waters USD 405M 11M 2026-06
West Pharmaceutical Services USD 117.6M 18.1M 2026-06